高风险MDS的前线治疗选择:我们可以超越azacitidine吗?
1Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL.
Hematology. American Society of Hematology. Education Program
|December 9, 2023
概括
尽管已经进行了17年多的研究,但没有一个随机试验对阿扎西蒂丁在高风险的骨髓质瘤 (MDS) 中有所改善. 新的组合疗法看起来很有前途,结果令人期待.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 阿扎西提丁是高风险骨髓质疏松性瘤 (MDS) 的标准护理.
- 尽管进行了广泛的研究,但没有一个随机试验证明其优于阿扎西蒂丁.
- 现实世界的数据显示,平均整体生存时间为14-18个月,反应率为40-50%.
研究的目的:
- 审查当前高风险MDS治疗的现状.
- 突出之前的比较试验中的挑战和局限性.
- 讨论新兴的组合疗法和未来的方向.
主要方法:
- 临床试验数据和真实世界的证据对高风险的MDS中阿扎西蒂丁的审查.
- 分析之前随机对照试验失败的原因.
- 讨论最近在MDS分类和预测方面的进展.
主要成果:
- 与阿扎西提丁相比,六项随机对照试验未能改善结果.
- 之前的试验中的方法问题包括不适当的剂量和缺乏安慰剂对照.
- 新兴的组合,如阿扎西蒂丁+维内托克拉克斯,+萨巴托利马布和+马格罗利马布在早期研究中显示出有前途.
结论:
- 在高风险的MDS中,急需新的治疗策略.
- 正在进行的新组合的安慰剂对照试验至关重要.
- 分子预测和更新的分类系统正在改变MDS管理.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


